Worth reading
51Recurring
Scored from 4 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
1923539164
Yen (continued listing criterion: ¥4 billion or more)Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
FormulatedWhat happened to the previous planNot disclosed → Sales in the safety and related fields continued to fall below the plan
Statements about the use of capital
Self-assessment of PBR and share priceThe company assesses that its share price has been depressed due to insufficient information disclosure and other factors. PBR: Not disclosed.PBR is a measure of how many times the share price is the book value per share.
Key initiatives
01Performance Improvement
02Strengthening IR activities
Plan assumptionsMarket capitalization was ¥1,923,539,164 at the end of March 2026, compared with a continued listing criterion of ¥4 billion or more. The improvement period runs through March 2027.
Risks identified by the company
Structural shift in the general laboratory animal market (market contraction)
Competition from the emergence of advanced preclinical models, including in silico models, PDX models, humanized models, MPS and organoids
Increasing uncertainty in the availability of donor-derived human hepatocytes for use in drug discovery research
Transportation costs associated with global expansion
Designation as a security subject to delisting and delisting if compliance with the market capitalization criterion is not confirmed during the improvement period
| Item | Details |
|---|---|
| Plan name | Plan to Meet the Listing Maintenance Criteria |
| Plan period | Starting fiscal year Not disclosed / Final year By March 2027 |
| Progress against the plan | Formulated |
| Self-assessment of PBR and share price | The company assesses that its share price has been depressed due to insufficient information disclosure and other factors. PBR: Not disclosed. |
| Plan assumptions | Market capitalization was ¥1,923,539,164 at the end of March 2026, compared with a continued listing criterion of ¥4 billion or more. The improvement period runs through March 2027. |
| Key initiatives | Performance Improvement, Strengthening IR activities |
| Results under the previous plan | Not disclosed → Sales in the safety and related fields continued to fall below the plan |
| Risks identified | Structural shift in the general laboratory animal market (market contraction), Competition from the emergence of advanced preclinical models, including in silico models, PDX models, humanized models, MPS and organoids, Increasing uncertainty in the availability of donor-derived human hepatocytes for use in drug discovery research, Transportation costs associated with global expansion, Designation as a security subject to delisting and delisting if compliance with the market capitalization criterion is not confirmed during the improvement period |
| Publication date | 29 June 2026 |
Items this document does not state (16)
Sales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalTotal investment planInvestment amount by sectorSegment targetNon-financial targetsReason for revision or withdrawalSize of the Target MarketDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explains that the primary factor behind the depressed share price is its failure to demonstrate high growth potential through actual financial results and its inability to convey its growth potential adequately due to insufficient information disclosure. In addition, it was unable to achieve the targeted growth because of declining sales as the viral hepatitis market reached maturity and major pharmaceutical companies withdrew, as well as sales falling short of target in the safety and related fields.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.